natgillin/translations-raw huggingface dataset:
Study results with tranexamic acid suggest reduced blood loss and reduced blood product requirements in paediatric cardiac surgery under cardiopulmonary bypass (CPB) where there is a high risk of haemorrhage, especially in cyanotic patients or patients undergoing repeat surgery. 
Rezultati študije kažejo, da traneksaminska kislina pri pediatričnih kirurških posegih na srcu - kardiopulmonalni obvod (CPB, cardiopulmonary bypass) , pri katerih obstaja velika nevarnost krvavitve, zlasti pri cianotičnih bolnikih ali pri bolnikih, pri katerih je treba operacijo ponoviti, zmanjša izgubo krvi in potrebo po krvnih pripravkih.
- Dermatitis allergic 
- alergijski dermatitis bolezni prebavil pogosto
Medicinal products that act on haemostasis should be given with caution to patients treated with tranexamic acid. 
Pri bolnikih, ki se zdravijo s traneksaminsko kislino je potrebna previdnost pri uporabi zdravil, ki delujejo na hemostazo.
- Arterial or venous thrombosis at any sites 
- arterijska ali venska tromboza na katerem koli mestu bolezni imunskega sistema ni znano
With pathological ophthalmic changes, particularly with diseases of the retina, the physician must decide after consulting a specialist on the necessity for the long-term use of TXA solution for injection in each individual case. 
Če so prisotne patološke spremembe, zlasti bolezni mrežnice, mora zdravnik po posvetu s specialistom odločiti, ali je dolgotrajno jemanje TXA raztopine za injiciranje, primerno za posameznega bolnika.
Undesirable Effects 
Možni neželeni učinki
Tranexamic acid passes through the placenta. 
Traneksaminska kislina prehaja skozi placento.
- Visual disturbances including impaired colour vision 
- motnje vida, vključno z motnjami barvnega vida žilne bolezni ni znano
With pathological ophthalmic changes, particularly with diseases of the retina, your doctor must take a decision after consulting a specialist on the necessity for the long-term use of <Tranexamic acid-containing medicinal products> solution for injection in your case. 
Če so prisotne patološke spremembe, zlasti bolezni mrežnice, mora vaš zdravnik po posvetu s specialistom odločiti, ali je dolgotrajno jemanje <zdravila, ki vsebujejo traneksaminsko kislino> raztopine za injiciranje za vas primerno.
6.5 Nature and contents of container [To be completed nationally] 
6.5 Vrsta ovojnine in vsebina [dopolni država članica]
Hypersensitivity to the active substance or to any of its excipients listed in section 6.1. 
• preobčutljivost za zdravilno učinkovino ali katerokoli pomožno snov, navedeno v poglavju
There is a theoretical risk of increased thrombus-formation potential, such as with oestrogens. 
Teoretično je tveganje za nastanek trombusov (krvnih strdov) večje kot pri zdravljenju z estrogeni.
Elderly: No reduction in dosage is necessary unless there is evidence of renal failure. 
Starejši Zmanjšanje odmerka ni potrebno, razen pri dokazani ledvični odpovedi.
• have kidney problems. 
• imate težave z ledvicami;
Standard treatment of general fibrinolysis: 1 g (1 ampule of 10 ml or 2 ampules of 5 ml) tranexamic acid by slow intravenous injection (= 1 ml/minute) every 6 to 8 hours, equivalent to 15 mg/kg BW 
1 g (1 ampula po 10 ml ali 2 ampuli po 5 ml) traneksaminske kisline, počasno intravensko injiciranje (= 1 ml/minuto) vsakih 6 do 8 ur, kar ustreza 15 mg / kg telesne mase.
- Haemorrhagic urinary disorders, further to prostate surgery or surgical procedures affecting the urinary tract, - Ear Nose Throat surgery (adenoidectomy, tonsillectomy, dental extractions), - Gynaecological surgery or disorders of obstetric origin, - Thoracic and abdominal surgery and other major surgical intervention such as cardiovascular surgery, - Management of haemorrhage due to the administration of a fibrinolytic agent. 
- krvavitev v sečilih, po operaciji prostate ali kirurških posegih na sečilih, - kirurški poseg na ušesu, nosu ali grlu (adenoidektomija, tonzilektomija, puljenje zob), - ginekološki kirurški poseg ali bolezni zaradi poroda, - kirurški poseg na prsnem košu in trebuhu teri drugi večji kirurški posegi, kot je srčnožilni kirurški poseg, - obvladovanje krvavitev, nastalih zaradi uporabe fibrinolitikov.
Cases of convulsions have been reported in association with tranexamic acid treatment. 
V povezavi z zdravljenjem s traneksaminsko kislino so poročali o primerih konvulzij.
Tranexamic acid is excreted in human milk. 
Traneksaminska kislina se izloča v materino mleko.
No specific dose-effect study or PK study has been conducted in children. 
Pri otrocih niso naredili nobene posebne študije razmerja med odmerkom in učinkom ali farmakokinetične študije.
If you a kidney problem, your dose of tranexamic acid will be reduced according to a test performed on your blood (serum creatinine level). 
Če imate okvarjeno delovanje ledvic, vam bo zdravnik zmanjšal odmerek traneksaminske kisline in sicer glede na raven serumskega kreatinina v krvi.
Excretion of tranexamic acid is about 90% within the first 24 hours after intravenous administration of 10 mg/kg body weight. 
V prvih 24 urah po intravenskem odmerjanju 10 mg/kg telesne mase se izloči približno 90 % traneksaminske kisline.
• If you have had convulsions, <Tranexamic acid - containing medicinal products> should not be administered. 
• če ste v preteklosti imeli epileptične krče, zdravila <zdravila, ki vsebujejo traneksaminsko kislino> ne smete uporabljati.
Method of administration <Tranexamic acid - containing medicinal products> should only be administrated slowly into a vein. 
Način uporabe zdravila <Zdravila, ki vsebujejo traneksaminsko kislino> je treba aplicirati počasi in sicer samo v veno.
Acute venous or arterial thrombosis (see section 4.4 Special) Fibrinolytic conditions following consumption coagulopathy except in those with predominant activation of the fibrinolytic system with acute severe bleeding (see section 4.4) Severe renal impairment (risk of accumulation) 
• fibrinolitična stanja po porabni koagulopatiji, razen pri tistih s prevladujočo aktivacijo fibrinolitičnega sistema z resno akutno krvavitvijo (glejte poglavje 4.4);
Visual disturbances 
Motnje vida
What you need to know before you are given <Tranexamic acid - containing medicinal products> 
Kaj morate vedeti, preden vam zdravnik da zdravilo <zdravila, ki vsebujejo traneksaminsko kislino>
MARKETING AUTHORISATION NUMBER(S) [To be completed nationally] DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION [To be completed nationally] 10. 
ŠTEVILKA (ŠTEVILKE) DOVOLJENJA (DOVOLJENJ) ZA PROMET Z ZDRAVILOM [dopolni država članica] DATUM PRIDOBITVE/PODALJŠANJA DOVOLJENJA ZA PROMET Z ZDRAVILOM [dopolni država članica]
6.6 Special precautions for disposal and other handling [To be completed nationally] 
6.6 Posebni varnostni ukrepi za odstranjevanje in ravnanje z zdravilom [dopolni država članica]
Nervous system disorders Not known 
- driska - bruhanje - slabost bolezni živčnega sistema ni znano
Tranexamic acid should be administered with care in patients receiving oral contraceptives because of the increased risk of thrombosis (See section 4.5. 
Pri bolnikih, ki jemljejo peroralne kontraceptive, je zaradi povečanega tveganja za trombozo traneksaminsko kislino treba dajati previdno (glejte poglavje 4.5.
In such acute cases a single dose of 1g tranexamic acid is frequently sufficient to control bleeding.. Administration of Tranexamic acid in DIC should be considered only when appropriate haematological laboratory facilities and expertise are available. 
V takih akutnih primerih za zaustavitev krvavitve pogosto zadostuje enkratni odmerek 1 g traneksaminske kisline.
• have a history of convulsions. 
• konvulzije v anamnezi;
• blood clots 
- krvni strdki
Ask your doctor for advice if you are pregnant or breast-feeding before taking <Tranexamic acidcontaining medicinal products>. 
Če ste noseči ali dojite, se pred jemanjem <zdravil, ki vsebujejo traneksaminsko kislino> posvetujte s svojim zdravnikom.
Dose IV 
IV odmerek odmerjanje
Specific indications include: - Heavy periods in women - Gastrointestinal bleeding - Haemorrhagic urinary disorders, further to prostate surgery or surgical procedures affecting the urinary tract - Ear, nose, or throat surgery heart, abdominal, or gynecological surgery bleeding after you have been treated with another medicine to break down blood clots. 
Posebne indikacije so: - močne menstruacije pri ženskah; - krvavitev iz prebavil; - krvavitev v sečilih, po operaciji prostate ali operacijah na sečilih - operacija ušes, nosu ali grla
What <Tranexamic acid - containing medicinal products> is and what it is used for 
KAJ JE ZDRAVILO <zdravila, ki vsebujejo traneksaminsko kislino> IN ZA KAJ GA UPORABLJAMO
4.7 Effects on ability to drive and use machines No studies have been performed on the ability to drive and use machines. 
4.7 Vpliv na sposobnost vožnje in upravljanje s stroji
The plasma protein binding of tranexamic acid is about 3% at therapeutic plasma levels and seems to be fully accounted for by its binding to plasminogen. 
Pri terapevtskih plazemskih koncentracijah se na plazemske beljakovine veže približno 3 % traneksaminske kisline.
If you are given more <Tranexamic acid - containing medicinal products> than the recommended dose 
Če ste prejeli večji odmerek zdravila <zdravila, ki vsebujejo traneksaminsko kislino> kot bi smeli
How to store <Tranexamic acid - containing medicinal products> 
KAKO UPORABLJATI ZDRAVILO <zdravila, ki vsebujejo traneksaminsko kislino>
NAME OF THE MEDICINAL PRODUCT Tranexamic acid containing medicinal products [See Annex I - To be completed nationally] 
NAVODILO ZA UPORABO Navodilo za uporabo <zdravila, ki vsebujejo traneksaminsko kislino> <[glejte Dodatek I - dopolni država članica]>
Annex III Summary of Product Characteristics and Package Leaflet 
Predlagano besedilo za povzetek glavnih značilnosti zdravila in navodilo za uporabo
Not known 
bolezni oči ni znano
Side effects reported with <Tranexamic acid - containing medicinal products> are: The following side effects have been observed with <Tranexamic acid - containing medicinal products> 
Neželeni učinki zdravila <zdravila, ki vsebujejo traneksaminsko kislino> so: Naslednje neželene učinke so opazili pri <zdravila, ki vsebujejo traneksaminsko kislino>: Pogosti neželeni učinki (se lahko pojavijo pri največ 1 od 10 bolnikov):
Hepatic impairment No dose adjustment is required in patient with hepatic impairment. 
Okvara jeter Pri bolnikih z okvaro jeter prilagajanje odmerka ni potrebno
4.2 Posology and method of administration Posology Adults Unless otherwise prescribed, the following doses are recommended: 1. 
Če ni drugače določeno, se priporočajo naslednji odmerki:
6.1 List of excipients [To be completed nationally] 
6.1 Seznam pomožnih snovi [dopolni država članica]
What you need to know before you are given <Tranexamic acid - containing medicinal products> Do not take <Tranexamic acid - containing medicinal products> if you: 
Ne uporabljajte zdravila <zdravila, ki vsebujejo traneksaminsko kislino>, če:
- Gastrointestinal bleeding, 
- krvavitev iz prebavil,
Marketing Authorisation Holder and Manufacturer 
IMETNIK DOVOLJENJA ZA PROMET Z ZDRAVILOM
In coronary artery bypass graft (CABG) surgery, most of these cases were reported following intravenous (i.v.) 
Večino teh primerov so poročali po intravenski (i. v.) injekciji traneksaminske kisline v visokih odmerkih in sicer pri kirurškem posegu vstavitve srčnega obvoda.
<Tranexamic acid - containing medicinal products> 
Shranjevanje zdravila <zdravila, ki vsebujejo traneksaminsko kislino> 6.
Common (may affect up to 1 in 10 users) • effects on the stomach and intestines: nausea, vomiting, diarrhoea 
• neželeni učinki na želodcu in v prebavilih: slabost, bruhanje, driska Občasni neželeni učinki (se pojavijo pri 1 do 10 od 1000 zdravljenih bolnikov)
What <Tranexamic acid - containing medicinal products> looks like and contents of the pack 
Izgled zdravila <zdravila, ki vsebujejo traneksaminsko kislino> in vsebina pakiranja [dopolni država članica]
Paediatric Population: 
Običajno zdravljenje lokalne fibrinolize:
How to store <Tranexamic acid - containing medicinal products> Contents of the pack and other information 
VSEBINA PAKIRANJA IN DRUGE INFORMACIJE Kaj vsebuje zdravilo <zdravila, ki vsebujejo traneksaminsko kislino> [dopolni država članica]
112 tablets 
112 tablet
200 mg Film-coated tablet 
200 mg filmsko obložena tableta peroralna uporaba pretisni omot (PP/Alu)
Invented name Strength Pharmaceutical Form Route of administration Packaging 
Izmišljeno ime Jakost
Oral use 
Pot uporabe
Do not use chemical disinfectants. 
Ne uporabljajte kemičnih razkužil.
Do not thaw in hot or ice cold water. 
Ne odmrzujte v vroči ali ledeno mrzli vodi.
ATCvet code: QI01AD. 
Oznaka ATC vet: QI01AD..
ILT: 4 weeks, MD: 9 days. 
ILT: 4 tedni MB: 9 dni
CAUTION: Ampoules have been known to explode on sudden temperature changes. 
PREVIDNOST: Znano je, da ampule eksplodirajo ob nenadnih spremembah temperature.
However, precautionary measures have to be followed in order to avoid direct or indirect contact between vaccinated chickens and turkeys. 
Vendar pa je treba upoštevati previdnostne mere, da se izognemo neposrednemu ali posrednemu stiku med cepljenimi piščanci in purani.
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 03/07/2015 
Datum pridobitve dovoljenja za promet: 03/07/2015
If you notice any serious effects or other effects not mentioned in this package leaflet, please inform your veterinary surgeon. 
Če opazite kakršne koli resne stranske učinke ali druge učinke, ki niso omenjeni v tem navodilu za uporabo, obvestite svojega veterinarja.
Care should be exercised to prevent contaminating your hands, eyes and clothing with the suspension. 
Paziti morate, da ne kontaminirate rok, oči in obleke s suspenzijo.
It is recommended to handle a maximum of 5 ampoules (from one cane only) at a time. 
Priporočljivo je, da delate z največ 5 ampulami (samo iz enega niza) naenkrat.
The excipients (including adjuvants) listed in section 6.1 of the SPC are either allowed substances for which table 1 of the annex to Commission Regulation (EU) No 37/2010 indicates that no MRLs are required or considered as not falling within the scope of Regulation (EC) No 470/2009 when used as in this veterinary medicinal product. 
SPC, so bodisi dovoljene snovi, za katere tabela 1 priloge Uredbe Komisije (EU) št.37/2010 določa, da MRL ni potreben ali pa, kot so uporabljene v tem zdravilu za uporabo v veterinarski medicini, niso vključene v Uredbo (ES) št.
Do not mix with any other veterinary medicinal product except Nobilis Rismavac and the solvent supplied for use with the veterinary medicinal product. 
Ne mešajte z nobenim drugim zdravilom za uporabo v veterinarski medicini razen s cepivom Nobilis Rismavac in z vehiklom, ki je namenjen za uporabo z zdravilom za uporabo v veterinarski medicini.
Disinfect vaccinating equipment by boiling in water for 20 minutes or by autoclaving (15 minutes at 121 °C). 
Razkužite opremo za cepljenje s kuhanjem v vreli vodi 20 minut ali pa v avtoklavu (15 minute pri 121 °C).
No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product except the products mentioned above. 
Ni podatkov o varnosti in učinkovitosti ob uporabi tega cepiva s katerim koli drugim zdravilom za uporabo v veterinarski medicini razen z omenjenimi.
No information is available on use in future breeding birds. 
Na voljo ni nobenih informacij o uporabi pri bodočih matičnih jatah.
Safety and efficacy data are available which demonstrate that this vaccine can be administered on the same day, but not mixed with, Nobilis ND Clone 30 or Nobilis ND C2. 
Podatki o varnosti in učinkovitosti so pokazali, da se to cepivo lahko da na isti dan vendar ne zmešano s cepivom Nobilis ND Clone 30 ali Nobilis ND C2.
For this mixed use, an onset of immunity of 5 days has been demonstrated for MD. 
Pri taki mešani uporabi se je pokazalo, da se pri MB imunost začne po 5 dneh.
It is important that the suspension, after being thawed, is mixed immediately into the solvent to protect the cells. 
Pomembno je, da supenzijo takoj, ko se otopi, zmešate v vehikel, da zaščitite celice.
Bovine serum Basal medium Dimethyl sulfoxide 
Suspenzija: goveji serum bazalni medij dimetil sulfoksid
Use 400 ml of solvent for each 2,000 doses of cell suspension or 800 ml of solvent for each 4,000 doses of cell suspension. 
Uporabite 400 ml vehikla za vsakih 2.000 odmerkov suspenzije celic ali 800 ml vehikla za vsakih 4.000 odmerkov suspenzije celic.
Any person intending to manufacture, import, possess, sell, supply and/or use Innovax-ILT must consult the relevant Member State's competent authority on the current vaccination policies prior to the manufacture, import, possession, sale, supply and/or use. 
Vsakdo, ki namerava izdelovati, uvažati /vnašati, posedovati, prodajati, oskrbovati in/ali uporabljati Innovax-ILT, se mora posvetovati s pristojnim organom posamezne države članice o veljavnih programih cepljenja še pred izdelavo, uvozom/ vnosom, posedovanjem, prodajo, oskrbo in/ali uporabo.
Preparation of the vaccine shall be planned before the ampoules are taken from the liquid nitrogen and the exact amount of vaccine ampoules and amount of solvent needed shall be calculated first. 
Pripravo cepiva je treba načrtovati, preden vzamete ampule iz tekočega dušika in najprej je treba izračunati točno količino ampul cepiva in količino potrebnega vehikla.
(number of doses per ampoule is presented on the colour coded clip attached to each cane containing the ampoule) 
(Število odmerkov na ampulo je navedeno na oznaki vsakega niza ampul.)
When this product is mixed with Nobilis Rismavac, both should be diluted in the same solvent bag in the same way (400 ml of solvent for each 2,000 doses of both products or 800 ml of solvent for each 4,000 doses of both products). 
Kadar to cepivo mešate s cepivom Nobilis Rismavac, je treba oba redčiti v isti vrečki z vehiklom na isti način (400 ml vehikla za vsakih 2.000 odmerkov obeh cepiv ali 800 ml vehikla za vsakih 4.000 odmerkov obeh cepiv.
When Innovax-ILT is mixed with Nobilis Rismavac the development of immunity towards ILT may be delayed in animals with maternally derived antibodies. 
Kadar se Innovax-ILT meša s cepivom Nobilis Rismavac, se razvoj imunosti za ILT lahko zakasni pri živalih, ki so dobile maternalna protitelesa.
After adding the content of the ampoule to the solvent, the ready to use product is a clear, red coloured suspension for injection. 
Ko ste vsebino ampule dodali vehiklu, je pripravek za uporabo bistra, rdeče obarvana suspenzija za injiciranje.
Overdose (symptoms, emergency procedures, antidotes): No symptoms were observed after the administration of a 10-fold dose of vaccine. 
Preveliko odmerjanje (simptomi, nujni ukrepi, protistrupi) Po dajanju 10kratnega odmerka cepiva niso bili opaženi nobeni simptomi.
Pancreatic digest of casein Phenolsulfonphthalein (Phenol red) Potassium dihydrogen phosphate Water for injections 
Vehikel: saharoza pankreasni presnovek kazeina fenolsulfonftalein (rdeči fenol) kalijev dihidrogenfosfat voda za injekcije
Shelf life after reconstitution according to directions: 2 hours at a temperature below 25 °C. 
Rok uporabnosti po rekonstituciji v skladu z navodili: 2 uri pri temperaturi pod 25 °C.
The manufacture, import, possession, sale, supply and/or use of Innovax-ILT may be prohibited in a Member State on the whole or part of its territory pursuant to national legislation. 
Izdelava, uvoz/vnos, posedovanje, prodaja, oskrba in/ali uporaba cepiva Innovax-ILT je lahko v državi članici prepovedana na njenem celotnem ozemlju ali delu ozemlja v skladu z nacionalno zakonodajo.
Marketing authorisation holder and manufacturer responsible for batch release: Intervet International B.V. 
Imetnik dovoljenja za promet z zdravilom in izdelovalec, odgovoren za sproščanje serij Intervet International B.V.
Gently withdraw the contents of the ampoule into a sterile syringe, mounted with an 18 gauge needle. 
Narahlo potegnite vsebino ampule v sterilno brizgo z 18 gauge iglo.
During subcutaneous vaccination, care should be taken to prevent damage of the blood vessels in the neck of the chickens. 
Pri subkutanem cepljenju je treba paziti, da ne poškodujemo ožilja na vratu piščancev.
As a live vaccine, the vaccine strain is excreted from vaccinated birds and may spread to turkeys. 
Ker je cepivo živo, se vakcinalni sev izloči iz cepljenih živali in se lahko razširi na purane.
Pharmacotherapeutic group: immunologicals for Aves, live viral vaccines for domestic fowls. 
IMUNOLOŠKE LASTNOSTI Farmakoterapevtska skupina: Imunološka sredstva za perutnino, živa virusna cepiva za domačo perutnino.
Innovax-ILT is a virus suspension packed in glass ampoules and stored in liquid nitrogen. 
Innovax-ILT je virusna suspenzija, pakirana v steklenih ampulah in hranjena v tekočem dušiku.
Store and transport frozen in liquid nitrogen (-196 °C). 
Shranjujte in prevažajte zmrznjeno v tekočem dušiku (-196 °C).
QUALITATIVE AND QUANTITATIVE COMPOSITION Each dose (0.2 ml) of reconstituted vaccine contains: 
Vsak odmerek (0,2 ml) rekonstituiranega cepiva vsebuje:
Shelf life of the cell suspension as packaged for sale: 3 years. 
Rok uporabnosti suspenzije celic v pakiranju za prodajo: 3 leta
For this reason, thaw the ampoules in clean water at 25-27 °C. 
Ampule odmrzujte v čisti vodi pri 25-27 °C.
For the full list of excipients, see section 6.1. 
1 PFU: enote, ki tvorijo plak Za celoten seznam pomožnih snovi glejte poglavje 6.1.
Fertility: No information is available on use in future breeding birds. 
Plodnost Ni podatkov o uporabi pri bodočih matičnih jatah.
Cell suspension: 
Suspenzija celic
Insert the needle through the stopper of the solvent bag and add slowly and gently the contents of the syringe to the solvent. 
Iglo zabodite skozi zamašek vrečke z vehiklom in vsebino brizge počasi in narahlo dodajte vehiklu.
No symptoms were observed after the administration of a 10-fold dose of vaccine. 
Po dajanju 10kratnega odmerka cepiva niso bili opaženi nobeni simptomi.
The vaccine induces active immunity against infectious laryngotracheitis and Marek's disease in chickens. 
Cepivo spodbudi aktivno imunost proti kužnemu laringotraheitisu in Marekovi bolezni pri piščancih.
Safety and efficacy data are available which demonstrate that Innovax-ILT can be mixed in the same solvent and administered with Nobilis Rismavac in Member States where this vaccine is authorized. 
Podatki o varnosti in učinkovitosti so pokazali, da se cepivo Innovax-ILT lahko meša v istem vehiklu in da s cepivom Nobilis Rismavac v državah članicah, kjer je to cepivo registrirano.
Withdraw a portion of the solvent into the syringe to rinse the ampoule. 
Potegnite del vehikla v brizgo, da sperete ampulo.
In case of an accident to prevent serious wounds by either the liquid nitrogen or the ampoules when removing an ampoule from the canister, hold palm of gloved hand away from body and face. 
Da bi v primeru nezgode preprečili hude rane bodisi s tekočim dušikom ali pa z ampulami, med jemanjem ampule iz posod držite dlan orokavičene roke stran od telesa in obraza.
The vaccine is administered by subcutaneous injection in the neck. 
Cepivo damo subkutano v vrat.
- 400 ml polyethylene or multilayer plastic bags of solvent. 
- 400 ml polietilenske ali večslojne plastične vrečke vehikla - 800 ml polietilenske ali večslojne plastične vrečke vehikla
The content of the ampoule(s) is thawed rapidly by immersing in clean water at 25-27 °C. 
Vsebina ampul(e) se hitro otopi, ko jo potopite v čisto vodo pri temperaturi 25-27 °C.
4.2 Indications for use, specifying the target species For active immunisation of one-day-old chicks to reduce mortality, clinical signs and lesions due to infection with avian infectious laryngotracheitis (ILT) virus and Marek's disease (MD) virus. 
4.2 Indikacije za uporabo pri ciljnih živalskih vrstah Za aktivno imunizacijo enodnevnih piščancev za zmanjšanje smrtnosti, kliničnih znakov in poškodb zaradi infekcije z virusom aviarnega infekcijskega laringotraheitisa (ILT) in virusa Marekove bolezni (MB).